89bio, Inc.
ETNB
$9.03
-$0.39-4.14%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.64M | 41.29M | 39.62M | 36.53M | 33.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 465.68M | 403.29M | 384.66M | 303.86M | 191.26M |
| Operating Income | -465.68M | -403.29M | -384.66M | -303.86M | -191.26M |
| Income Before Tax | -448.86M | -385.94M | -366.39M | -284.66M | -170.51M |
| Income Tax Expenses | 1.35M | 732.00K | 692.00K | 4.30M | 4.10M |
| Earnings from Continuing Operations | -450.21 | -386.67 | -367.08 | -288.96 | -174.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -450.21M | -386.67M | -367.08M | -288.96M | -174.61M |
| EBIT | -465.68M | -403.29M | -384.66M | -303.86M | -191.26M |
| EBITDA | -465.64M | -403.25M | -384.62M | -303.81M | -191.22M |
| EPS Basic | -3.61 | -3.38 | -3.43 | -2.91 | -1.97 |
| Normalized Basic EPS | -2.27 | -2.13 | -2.17 | -1.82 | -1.24 |
| EPS Diluted | -3.61 | -3.38 | -3.43 | -2.91 | -1.97 |
| Normalized Diluted EPS | -2.27 | -2.13 | -2.17 | -1.82 | -1.24 |
| Average Basic Shares Outstanding | 527.28M | 469.23M | 418.71M | 383.45M | 352.71M |
| Average Diluted Shares Outstanding | 527.28M | 469.23M | 418.71M | 383.45M | 352.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |